Clinical Trials Logo

Salivary Gland Adenocarcinoma clinical trials

View clinical trials related to Salivary Gland Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT00126607 Terminated - Clinical trials for Recurrent Salivary Gland Cancer

Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well trastuzumab works in treating patients with metastatic or recurrent salivary gland cancer. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them

NCT ID: NCT00095563 Completed - Clinical trials for Recurrent Salivary Gland Cancer

Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers

Start date: September 2004
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of lapatinib in treating patients who have recurrent and/or metastatic adenoid cystic cancer or other salivary gland cancers. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

NCT ID: NCT00028496 Completed - Clinical trials for Stage IV Breast Cancer

Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Start date: November 2001
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may make tumor cells more sensitive to the vaccine and may kill more tumor cells